
Press Release|Articles|October 28, 2024
Camber Launches Generic Neurontin®
Listen
0:00 / 0:00
Key Takeaways
- Camber Pharmaceuticals introduces Gabapentin Oral Solution, expanding its existing gabapentin product offerings.
- Indications include management of postherpetic neuralgia in adults and adjunctive therapy for partial onset seizures in patients aged three and older.
Advertisement
Piscataway, NJ, October 25, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Gabapentin Oral Solution to its product line. Camber also offers Gabapentin Tablets and Capsules.
Gabapentin Oral Solution is indicated for:
- Management of Postherpetic Neuralgia in adults
- Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy
Gabapentin Oral Solution is available in a 470 mL bottle with a concentration of 250 mg per 5 mL.
To learn more about Gabapentin Oral Solution, please visit
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says
3
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
4
ADA 2026: Semaglutide Add-On Reduces Glycemic Burden, Cardiometabolic Risk in Older Adults With T2D
5
































































































































